Claritas Pharmaceuticals, Inc.

CLAZF · OTC
Analyze with AI
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Assets
Cash & Equivalents$0$0$0$4
Short-Term Investments$0$0$0$0
Receivables$0$0$1$0
Inventory$0-$0-$0-$0
Other Curr. Assets$1$0$0$0
Total Curr. Assets$1$0$1$4
Property Plant & Equip (Net)$0$0$0$0
Goodwill$2$5$9$11
Intangibles$8$20$49$50
Long-Term Investments$0$0$0$0
Tax Assets$0$0$0$0
Other NC Assets$0$0$0-$0
Total NC Assets$9$25$59$61
Other Assets$0$0$0$0
Total Assets$10$25$60$65
Liabilities
Payables$1$2$2$1
Short-Term Debt$1$0$0$0
Tax Payable$0$0$0$0
Deferred Revenue-$1-$2-$2$0
Other Curr. Liab.$5$4$6$3
Total Curr. Liab.$7$6$8$4
LT Debt$0$0$0$3
Deferred Rev, NC$0$3$0$17
Deferred Tax Liab, NC$2$7$11$11
Other NC Liab.$0$13$31$53
Total NC Liab.$2$23$42$73
Other Liabilities$0$0$0$0
Cap. Leases$0$0$0$0
Total Liabilities$9$29$50$77
Equity
Pref Stock$0$0$0$0
Common Stock$57$56$44$29
Retained Earnings-$55-$59-$38-$45
AOCI$57$56$48$33
Other Equity$0$56-$44$4
Total Equity$2-$3$10-$12
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$10$25$60$65
Net Debt$1$1$0-$1